Mission Bay Capital, the venture capital arm of California Institute for Quantitative Biosciences, helped the replacement therapy developer close its series B round.
US-based replacement therapy developer Glycomine completed a $68m series B round yesterday, securing $35m from a pool of investors including Mission Bay Capital, the venture capital arm of California Institute for Quantitative Biosciences (QB3).
Sanofi Ventures, the corporate venturing arm of pharmaceutical firm Sanofi, co-led the round with venture capital firm Abingworth. It included pharmaceutical companies Novo, Asahi Kasei and Chiesi Group, the latter two through Asahi Kasei Pharma Ventures and Chiesi Ventures.
The round also featured life…
